Comparison of the long-term tolerability, pharmacodynamics, and safety of Sandimmune and Neoral in liver transplant recipients

被引：0
|
作者：
Grant, D
Rochon, J
Levy, G
Cattral, M
Cheung, S
Grieg, P
Altraif, I
Rezieg, M
Wong, PY
Adams, P
Asfar, S
Freeman, D
Ghent, C
Wall, W
机构：
[1] UNIV WESTERN ONTARIO,TORONTO,ON,CANADA
[2] UNIV TORONTO,TORONTO,ON,CANADA
来源：
TRANSPLANTATION PROCEEDINGS | 1996年 / 28卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：2232 / 2233
页数：2
相关论文
共 50 条
  • [21] Long-term safety, tolerability and efficacy of daclizumab (Zenapax®) in a two-dose regimen in liver transplant recipients
    Niemeyer, G
    Koch, M
    Light, S
    Kuse, ER
    Nashan, B
    AMERICAN JOURNAL OF TRANSPLANTATION, 2002, 2 (05) : 454 - 460
  • [22] Comparison of the long-term efficacy and safety of generic tacrolimus, Tacrobell, with Prograf in liver transplant recipients
    Choi, Ho Joong
    Kim, Dong Goo
    Kwak, Bong Jun
    Han, Jae Hyun
    Hong, Tae Ho
    You, Young Kyoung
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 295 - 301
  • [23] Changing stable heart transplant recipients from sandimmune to neoral
    DalrympleHay, M
    Meara, M
    Reynolds, L
    Backhouse, L
    Wright, D
    Holt, D
    Johnston, A
    Madden, B
    Murday, A
    TRANSPLANTATION PROCEEDINGS, 1996, 28 (04) : 2285 - 2286
  • [24] Conversion from Sandimmune to Neoral in stable renal transplant recipients
    Pescovitz, MD
    TRANSPLANTATION PROCEEDINGS, 1996, 28 (04) : 2196 - 2198
  • [25] Conversion from sandimmune to neoral and induction therapy with neoral in pediatric renal transplant recipients
    Hoyer, PF
    Boekenkamp, A
    Vester, U
    Offner, G
    Brodehl, J
    TRANSPLANTATION PROCEEDINGS, 1996, 28 (04) : 2259 - 2261
  • [26] Safety and tolerability of Neoral vs Sandimmune: 1-year data in primary renal allograft recipients
    Barone, G
    Bunke, CM
    Choc, MG
    Hricik, DE
    Jin, JHJ
    Klein, JB
    Marsh, CL
    Min, DI
    Pescovitz, MD
    Pollak, R
    Pruett, TL
    Stinson, JB
    Thompson, JS
    Vasquez, E
    Waid, T
    Wombolt, DG
    Wong, RL
    TRANSPLANTATION PROCEEDINGS, 1996, 28 (04) : 2183 - 2186
  • [27] Safety of conversion from cyclosporine Sandimmune to cyclosporine Neoral in stable liver transplant patients
    Baruch, Y
    Assy, N
    Kramsky, R
    Enat, R
    TRANSPLANTATION PROCEEDINGS, 1998, 30 (05) : 1852 - 1853
  • [28] Conversion from Sandimmune to Neoral in stable liver graft recipients
    Pollard, SG
    Lodge, JPA
    TRANSPLANTATION PROCEEDINGS, 1996, 28 (04) : 2244 - 2246
  • [29] Impact of Sandimmune, Neoral, and Prograf on rejection incidence and renal function in primary liver transplant recipients
    Van Buren, D
    Payne, J
    Geevarghese, S
    MacDonell, R
    Chapman, W
    Wright, JK
    Helderman, JH
    Richie, R
    Pinson, CW
    TRANSPLANTATION PROCEEDINGS, 1998, 30 (05) : 1830 - 1832
  • [30] Pharmacokinetics of neoral in stable renal transplant recipients with long-term diabetes mellitus
    Deel, C.
    Nori, U.
    Pescovitz, M. D.
    Govani, M. V.
    TRANSPLANTATION PROCEEDINGS, 2007, 39 (01) : 109 - 114
12345